Standard BioTools Files 10-Q for Q2 2025

TL;DR

Standard BioTools 10-Q filed. Financials updated for Q2 2025. SomaScan business mentioned.

AI Summary

Standard BioTools Inc. filed its 10-Q for the period ending June 30, 2025. The company, formerly Fluidigm Corp, is involved in laboratory analytical instruments. Key dates mentioned include June 30, 2025, and August 15, 2025, for filing and reporting. The filing references various financial instruments and business segments, including the SomaScan business.

Why It Matters

This filing provides investors with an update on Standard BioTools' financial performance and operational status for the second quarter of 2025, impacting investment decisions.

Risk Assessment

Risk Level: medium — 10-Q filings inherently carry medium risk due to the detailed financial and operational information that can reveal company performance and future outlook.

Key Numbers

• Q2 --12-31 — Fiscal Quarter End (Indicates the reporting period for the 10-Q)
• 2025-06-30 — Reporting Period End (Specific date for the financial data presented)
• 2025-08-15 — Filing Date (Date the report was officially submitted to the SEC)

Key Players & Entities

• STANDARD BIOTOOLS INC. (company) — Filer
• FLUIDIGM CORP (company) — Former Company Name
• 20250630 (date) — Reporting Period End Date
• 20250815 (date) — Filing Date
• Somalogic Inc (company) — Mentioned in context of Director
• SomaScan Business (business_segment) — Mentioned in relation to Illumina
• Illumina (company) — Mentioned in relation to SomaScan Business

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share LAB The Nasdaq

Filing Documents

• lab-20250630.htm (10-Q) — 2960KB
• lab-ex10_1.htm (EX-10.1) — 74KB
• lab-ex31_1.htm (EX-31.1) — 17KB
• lab-ex31_2.htm (EX-31.2) — 18KB
• lab-ex32_1.htm (EX-32.1) — 10KB
• lab-ex32_2.htm (EX-32.2) — 10KB
• img188219300_0.jpg (GRAPHIC) — 178KB
• 0000950170-25-109388.txt ( ) — 11807KB
• lab-20250630.xsd (EX-101.SCH) — 1413KB
• lab-20250630_htm.xml (XML) — 2158KB

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 2 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and six months ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Cash Flows for six months ended June 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 30 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 33 EXHIBIT LIST 33

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

F inancial Statements

Item 1. F inancial Statements STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value) (Unaudited) June 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 158,617 $ 166,728 Short-term investments 78,468 126,146 Accounts receivable, net 14,612 14,741 Inventory 24,170 20,744 Prepaid expenses and other current assets 7,081 4,561 Current assets held for sale 223,089 42,963 Total current assets 506,037 375,883 Property and equipment, net 22,678 22,775 Operating lease right-of-use asset, net 24,568 26,567 Other non-current assets 3,682 3,688 Non-current assets held for sale — 183,432 Total assets $ 556,965 $ 612,345 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 7,329 $ 5,049 Accrued liabilities 24,207 21,435 Operating lease liabilities, current 5,094 4,806 Deferred revenue, current 40,167 10,274 Deferred grant income, current 3,243 3,527 Current liabilities held for sale 17,984 20,804 Total current liabilities 98,024 65,895 Convertible notes, non-current 299 299 Deferred tax liability 1,081 1,081 Operating lease liabilities, non-current 23,223 25,590 Deferred revenue, non-current 2,786 32,674 Deferred grant income, non-current 5,767 7,243 Other non-current liabilities 1,250 1,062 Non-current liabilities held for sale — 6,779 Total liabilities 132,430 140,623 Commitments and contingencies (Note 6) Stockholders' equity: Preferred stock: $ 0.001 par value, 10,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Common stock: $ 0.001 par value, 600,000 shares authorized at June 30, 2025 and December 31, 2024; 400,273 and 396,110 shares issued at June 30, 2025 and December 31, 2024, respectivel

View Full Filing

View this 10-Q filing on SEC EDGAR